Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: SOF/VEL/VOX in DAA-Experienced HCV
NCT02745535Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of voxilaprevir in hepatitis C (HCV), sponsored by University of Maryland, Baltimore. Started May 2016; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02745535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745535.